Stockreport

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Annovis Bio, Inc.  (ANVS) 
PDF Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout anticipated Q1 2027Alzheimer’s disease Phase 3 trial 75% enrolledParkinson' [Read more]